Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Treace Medical Concepts (TMCI) Accumulated Depreciation & Amortization (2020 - 2026)

Treace Medical Concepts filings provide 6 years of Accumulated Depreciation & Amortization readings, the most recent being $23.9 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 55.96% to $23.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.9 million, a 55.96% increase, with the full-year FY2025 number at $23.9 million, up 55.96% from a year prior.
  • Accumulated Depreciation & Amortization hit $23.9 million in Q4 2025 for Treace Medical Concepts, up from $21.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $23.9 million in Q4 2025 to a low of $117000.0 in Q1 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $6.6 million (2023), compared with a mean of $9.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: tumbled 61.51% in 2021 and later soared 2418.8% in 2022.
  • Treace Medical Concepts' Accumulated Depreciation & Amortization stood at $2.7 million in 2021, then skyrocketed by 55.64% to $4.3 million in 2022, then soared by 105.21% to $8.7 million in 2023, then skyrocketed by 74.95% to $15.3 million in 2024, then soared by 55.96% to $23.9 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $23.9 million (Q4 2025), $21.8 million (Q3 2025), and $19.6 million (Q2 2025) per Business Quant data.